| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 5, Issue 8 839-846, Copyright © 1994 by American Association of Cancer Research
ARTICLES |
CL Sommers, JM Skerker, SA Chrysogelos, M Bosseler and EP Gelmann
Department of Medicine, Georgetown University School of Medicine, Washington, DC 20007.
We have investigated the control of vimentin expression in human breast cancer cell lines because of its transcriptional activation during malignant progression in breast cancer. Comparison of vimentin-positive (V+) and vimentin-negative (V-) breast cancer cell lines revealed several potential areas of vimentin gene regulation. Analysis of the chromatin structure of the vimentin gene in V+ and V- breast cancer cells showed DNase I hypersensitive sites in the 5' promoter region in V+ cell lines and 3' to the start of transcription in V- cell lines. Promoter deletion and reporter gene analysis revealed the importance of two adjacent AP-1 sites separated by seven GC-rich nucleotides for vimentin expression in V+ breast cancer cells. Mutational analysis of these sequences showed that although both AP-1 sites could bind nuclear proteins from V+ cells in vitro, one AP-1 site was sufficient to drive transcription in CAT reporter gene assays. The GC-rich spacer region had a modulating function on the activity of the AP-1 sites. In addition, levels of c-jun mRNA were elevated in V+ versus V- cells. In summary, distinct sites within the vimentin gene appear to be important for the control of vimentin expression in V+ and V- breast cancer cells with multiple elements acting coordinately to regulate vimentin expression.
This article has been cited by other articles:
![]() |
X. Zhang, I. H. Diab, and Z. E. Zehner ZBP-89 represses vimentin gene transcription by interacting with the transcriptional activator, Sp1 Nucleic Acids Res., June 1, 2003; 31(11): 2900 - 2914. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gilles, M. Polette, M. Mestdagt, B. Nawrocki-Raby, P. Ruggeri, P. Birembaut, and J.-M. Foidart Transactivation of Vimentin by {beta}-Catenin in Human Breast Cancer Cells Cancer Res., May 15, 2003; 63(10): 2658 - 2664. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Zajchowski, M. F. Bartholdi, Y. Gong, L. Webster, H.-L. Liu, A. Munishkin, C. Beauheim, S. Harvey, S. P. Ethier, and P. H. Johnson Identification of Gene Expression Profiles That Predict the Aggressive Behavior of Breast Cancer Cells Cancer Res., July 1, 2001; 61(13): 5168 - 5178. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Reeves, D. D. Edberg, and Y. Li Architectural Transcription Factor HMGI(Y) Promotes Tumor Progression and Mesenchymal Transition of Human Epithelial Cells Mol. Cell. Biol., January 15, 2001; 21(2): 575 - 594. [Abstract] [Full Text] |
||||
![]() |
E. Sapi, M. B. Flick, K. Tartaro, S. Kim, Y. Rakhlin, S. Rodov, and B. M. Kacinski Effect of All-trans-Retinoic Acid on c-fms Proto-oncogene [Colony-stimulating Factor 1 (CSF-1) Receptor] Expression and CSF-1-induced Invasion and Anchorage-independent Growth of Human Breast Carcinoma Cells Cancer Res., November 1, 1999; 59(21): 5578 - 5585. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Gilles, M Polette, J. Zahm, J. Tournier, L Volders, J. Foidart, and P Birembaut Vimentin contributes to human mammary epithelial cell migration J. Cell Sci., January 12, 1999; 112(24): 4615 - 4625. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |